TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06362941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Hair Growth Supplemnt
Description: Hair growth supplement for women ages 18 - 44.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Balance Hair Growth Supplement
Description: Hair growth supplement for women ages 45 - 70.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Vegan Hair Growth Supplement
Description: Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Postpartum Hair Growth Supplement
Description: Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Men's Hair Growth Supplement
Description: Hair growth supplement for men ages 25 - 50.
Study: NCT06355817

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration
Description: Vibration Assist Device, held to the forehead
Study: NCT05277961

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Description: UV6 tubes
Study: NCT06355817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration Assist Device, held to the forehead

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tapping
Description: Tapping on the forehead

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapping
Description: Tapping on the forehead
Study: NCT05843721

Intervention type: DEVICE
Group type: OTHER
Intervention: KOS (Intranasal kinetic oscillation stimulation)
Description: Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
Study: NCT05190185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA06 injection
Description: The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
Study: NCT05882032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study: NCT05483842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Reiki
Description: Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
Study: NCT05333965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (lehfilcon A lens)
Description: Daily wear for 1 month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (lehfilcon A lens)
Description: Daily wear for 1 month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (comfilcon A lens)
Description: Daily wear for 1 month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (comfilcon A lens)
Description: Daily wear for 1 month.
Study: NCT05599633

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sago starch drink
Description: Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch drink
Description: Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
Study: NCT06431698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made silicone device
Description: Correction of deformation using the custom-made silicone device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: adjustable Earwell device
Description: Correction of deformation using the adjustable Earwell device
Study: NCT04708821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone ophthalmic insert 0.4Mg
Description: Dextenza 0.4Mg Ophthalmic Insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% loteprednol etabonate ophthalmic suspension
Description: 0.2% loteprednol etabonate ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride ophthalmic solution 0.7%
Description: olopatadine hydrochloride ophthalmic solution 0.7%
Study: NCT04847648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing
Description: Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical decontamination
Description: Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical decontamination
Description: Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
Study: NCT05153915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: Oral
Study: NCT05249998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program combing APA, Nutrition, and Therapeutic Education
Description: Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
Study: NCT06534463

Intervention type: OTHER
Intervention: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Description: The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Study: NCT05098600

Intervention type: OTHER
Intervention: Exposure of interest
Description: Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
Study: NCT04795427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asciminib
Description: Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: best available treatment
Description: Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
Study: NCT06190951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: Administered intravenous (IV) every 3 weeks (Q3W) Phase 3 active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered IV Q3W Phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered IV Q3W Phase 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cemiplimab
Description: Administered IV Q3W Phase 2 Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab+fianlimab
Description: Administered IV Q3W Phase 3 Either fianlimab HD or fianlimab LD in combination with cemiplimab will be chosen for Phase 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab+fianlimab
Description: Administered IV Q3W Phase 3 Either fianlimab HD or fianlimab LD in combination with cemiplimab will be chosen for Phase 3
Study: NCT05375747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
Study: NCT05550649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
Study: NCT06629142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Order
Description: A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
Study: NCT05550649

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: embolization
Description: Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
Study: NCT04621071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (2 strains 10x10^9 UFC)
Description: Probiotic vs Placebo (1:1)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (potato starch and magnesium stearate)
Description: Probiotic vs Placebo (1:1)
Study: NCT06297980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized modifications to treatment to address menstrual cycle effects on glycemia
Description: The study physician will examine glucose patterns measured using continuous glucose monitoring over a 3 month observational period to identify hypo- or hyperglycemia related to menstrual cycle phase or exercise, and will provide changes to insulin basal or bolus rates, carbohydrate ratios, post-exercise food intake or use of sleep mode on automated insulin delivery systems.
Study: NCT05897125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual at Home Medication Reconciliation Visit(s)
Description: Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
Study: NCT05247216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007 800 mg QD group
Description: daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007 1200 mg QD group
Description: daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007 600 mg QD group
Description: daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay007 placebo group
Description: daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
Study: NCT05897125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual At Home Medication Education Visit(s)
Description: Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD advanced practice nurse Inpatient Consult
Description: Patients will receive a COPD consult by an advanced practice nurse as part of standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD advanced practice nurse Inpatient Consult
Description: Patients will receive a COPD consult by an advanced practice nurse as part of standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inpatient Medication Reconciliation
Description: Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Medication Reconciliation
Description: Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-discharge nurse 48 hour phone follow-up call
Description: Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-discharge nurse 48 hour phone follow-up call
Description: Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-discharge follow-up advanced practice nurse outpatient visit
Description: Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-discharge follow-up advanced practice nurse outpatient visit
Description: Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
Study: NCT05250089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
Study: NCT05305339

Intervention type: OTHER
Intervention: Placental and Umbilical cord biopsy
Description: After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).

Intervention type: OTHER
Intervention: Placental and Umbilical cord biopsy
Description: After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).

Intervention type: OTHER
Intervention: Placental and Umbilical cord biopsy
Description: After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).

Intervention type: OTHER
Intervention: Placental and Umbilical cord biopsy
Description: After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
Study: NCT05588895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician.
Study: NCT05973630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATA-200
Description: single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATA-200
Description: single intravenous infusion
Study: NCT05793437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: permissive hypercapnia
Description: Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
Study: NCT06629142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Order
Description: A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountable Justification
Description: An EHR-based Our Practice Advisory alert asks generalist clinicians to self-report whether they have provided primary PC by clicking which of 4 key PC domains they have addressed or to provide a brief justification as to why not.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Usual Care
Description: Moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. For very high-risk patients (e.g., with a 1-year mortality risk of ≥ 95%), an EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
Study: NCT06053840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Description: Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
Study: NCT05793437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: normocapnia
Description: Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
Study: NCT05654441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: 0.5 mL single-dose injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL single-dose injection with no therapeutic effect